Rhabdomyolysis

Paper Summary:

The paper discusses how the federal Food and Drug Administration (FDA) reports that rhabdomyolysis as a rare, but well-known, side effect of all statins. The paper examines how Rhabdomyolysis takes place when extensive muscle damage results in the release of cellular contents into systemic circulation. The paper includes a case study of a patient presenting signs of rhabdomyolysis.

Outline:
Overview of Clinical Situation
Primary and Significant Secondary Medical Diagnoses
Medications
References

From the Paper:

"For example, according to Wren, Frizzell, Keltner, and Wright (2003), neuroleptic malignant syndrome (NMS) is a potentially fatal reaction to dopamine blockade that result from patients taking antipsychotic and other medications, and some of the symptoms of NMS are interrelated. "For example," they advise, "high temperatures may develop and can be exacerbated by massive muscle contraction and hypermetabolism. Rigidity also may cause rhabdomyolysis, which can lead to acute renal failure when kidneys are flooded with myoglobin. Severity is assessed by measurement of creatine phosphokinase (CPK). Renal failure is the most common cause of death in NMS" (p. 76)."

Sample of Sources Used:

• Agha, I. A. (2003). Rhabdomyolysis. In Medline Plus Medical Encyclopedia. Retrieved March 20, 2006 from http://www.nlm.nih.gov/medlineplus/ency/article/000473.htm.
• Baruch, E. M., Deerfield, L. J., & Rosenberg, M. H. (2003). Two cases of severe gamma- hydroxybutyrate withdrawal delirium on a psychiatric unit: Recommendations for management. American Journal of Drug and Alcohol Abuse, 29(2), 487.
• Frizzell, L. A., Keltner, N. L., Wren, P., & Wright, A. V. (2003). Three potentially fatal adverse effects of psychotropic medications. Perspectives in Psychiatric Care, 39(2), 75.
• Galea, S., Novoa, R. A., Ompad, D. C., Vlahov, D., & Wu, Y. (2005). Ecstasy use and its association with sexual behaviors among drug users in New York City. Journal of Community Health, 30(5), 331.
• New warning for statin drug. (2005, May/June). FDA Consumer, 39(3), 2.

APA Citation:

MLA Citation: